NCT02716246

Brief Summary

The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for phase_2

Timeline
14mo left

Started Apr 2016

Longer than P75 for phase_2

Geographic Reach
3 countries

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Apr 2016Jul 2027

First Submitted

Initial submission to the registry

March 17, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 23, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

April 25, 2016

Completed
11.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

11.2 years

First QC Date

March 17, 2016

Last Update Submit

April 21, 2026

Conditions

Keywords

MPS IIIASanfilippoGene Therapy

Outcome Measures

Primary Outcomes (1)

  • Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure

    Exposure is defined as the time-normalized area under the curve (AUC) of the percentage reduction from baseline.

    Up to Month 24 Visit

Secondary Outcomes (7)

  • Bayley Scales of Infant and Toddler Development-Third Edition (BSITD-III) Cognitive Raw Score Over Time

    Up to Month 24 Visit

  • CSF Ganglioside Type 2 (GM2) Exposure

    Up to Month 24 Visit

  • CSF Ganglioside Type 3 (GM3) Exposure

    Up to Month 24 Visit

  • Percent Change from Baseline in CSF HS

    Baseline, Up to Month 24 Visit

  • BSITD-III Receptive Communication Raw Score Over Time

    Up to Month 24 Visit

  • +2 more secondary outcomes

Other Outcomes (1)

  • Number of Participants with Treatment-Emergent Adverse Events, and Treatment-Emergent Serious Adverse Events

    Up to Month 24 Visit

Study Arms (4)

Cohort 1 Low Dose

EXPERIMENTAL

Dose of 0.5 X 10\^13 vg/kg

Biological: UX111Drug: Prophylactic Immunomodulatory (IM) TherapyDrug: Adjuvant IM Therapy

Cohort 2 Mid Dose

EXPERIMENTAL

Dose of 1 X 10\^13 vg/kg

Biological: UX111Drug: Prophylactic Immunomodulatory (IM) TherapyDrug: Adjuvant IM Therapy

Cohort 3 High Dose

EXPERIMENTAL

Dose of 3 X 10\^13 vg/kg

Biological: UX111Drug: Prophylactic Immunomodulatory (IM) TherapyDrug: Adjuvant IM Therapy

Cohort 4 High Dose (Spain Only)

EXPERIMENTAL

Dose of 3 X 10\^13 vg/kg

Biological: UX111Drug: Optimized Prophylactic IM TherapyDrug: Adjuvant IM Therapy

Interventions

UX111BIOLOGICAL

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

Also known as: scAAV9.U1a.hSGSH, ABO-102, rebisufligene etisparvovec
Cohort 1 Low DoseCohort 2 Mid DoseCohort 3 High DoseCohort 4 High Dose (Spain Only)
Cohort 1 Low DoseCohort 2 Mid DoseCohort 3 High Dose
Cohort 4 High Dose (Spain Only)

The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

Cohort 1 Low DoseCohort 2 Mid DoseCohort 3 High DoseCohort 4 High Dose (Spain Only)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of MPS IIIA confirmed by the following methods:
  • No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and
  • Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • Age:
  • For Cohort 1-3: From birth (participating sites in USA and Australia) OR 6 months (participating sites in Spain) to 2 years of age with no BSITD-III Cognitive Development Quotient (DQ) requirement, or older than 2 years with a BSITD-III Cognitive DQ of 60 or above (participating sites globally).
  • Cohort 4 only: Vaccination status based on age according to country-specific guidelines that is up to date 30 days prior to Enrollment as verified by documentation from the subject's primary care physician, and willing to defer vaccines through 6 months after completion of the subject's IM medication, or longer per Principal Investigator (PI) judgment. Emergency use authorization or conditional marketing authorization of coronavirus disease (COVID) vaccines is included unless there is an accepted medical exemption.

You may not qualify if:

  • Inability to participate in the clinical evaluation as determined by PI
  • Cohorts 1 to 3 only: Identification of two nonsense or null variants on genetic testing of the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • At least one S298P mutation in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • Has evidence of an attenuated phenotype of MPS IIIA, in the judgement of the PI
  • Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
  • Active viral infection based on clinical observations
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer or precludes the child from participating in the protocol assessments and follow up
  • Cohorts 1 to 3 only: Subjects with total anti-AAV9 antibody titers ≥ 1:100 equivalent to a positive screen as determined by ELISA binding assay in serum
  • Cohorts 1-3 only: Subjects with a positive response for the enzyme-linked immunosorbent spot assay (ELISpot) for T-cell responses to AAV9
  • Cohorts 1-3 only: Serology consistent with exposure to human immunodeficiency virus (HIV), or serology consistent with active hepatitis B or C infection, Cohort 4: Current clinically significant infections (including any requiring systemic treatment including, but not limited to, HIV; hepatitis A, B, or C; varicella zosters virus; human T-cell lymphotropic virus type 1 \[HTLV-1\]; tuberculosis; or COVID-19) that would interfere with participation in the study.
  • Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy
  • Visual, hearing, or other impairment sufficient to preclude cooperation with neurodevelopmental testing
  • Uncontrolled seizure disorder
  • Any item (braces, etc.) or circumstance that would exclude the subject from being able to undergo MRI according to local institutional policy
  • Any other situation that precludes the subject from undergoing procedures required in this study
  • +17 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

COMPLETED

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States

COMPLETED

Women's and Children's Hospital

North Adelaide, South Australia, 5006, Australia

COMPLETED

Vall d'Hebron Barcelona Hospital Campus

Barcelona, 08035, Spain

RECRUITING

Hospital Clínico Universitario de Santiago

Santiago de Compostela, 15706, Spain

RECRUITING

Related Publications (3)

  • Fu H, Cataldi MP, Ware TA, Zaraspe K, Meadows AS, Murrey DA, McCarty DM. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol Ther Methods Clin Dev. 2016 Jun 8;3:16036. doi: 10.1038/mtm.2016.36. eCollection 2016.

    PMID: 27331076BACKGROUND
  • Fu H, Meadows AS, Pineda RJ, Kunkler KL, Truxal KV, McBride KL, Flanigan KM, McCarty DM. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy. Hum Gene Ther Clin Dev. 2017 Dec;28(4):187-196. doi: 10.1089/humc.2017.109. Epub 2017 Oct 24.

    PMID: 29064732BACKGROUND
  • McCurdy VJ, Johnson AK, Gray-Edwards HL, Randle AN, Bradbury AM, Morrison NE, Hwang M, Baker HJ, Cox NR, Sena-Esteves M, Martin DR. Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease. Gene Ther. 2021 Apr;28(3-4):142-154. doi: 10.1038/s41434-020-00190-1. Epub 2020 Sep 3.

Related Links

MeSH Terms

Conditions

Mucopolysaccharidosis III

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

MucopolysaccharidosesCarbohydrate Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesLysosomal Storage DiseasesMucinosesConnective Tissue DiseasesSkin and Connective Tissue DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Medical Director

    Ultragenyx Pharmaceutical Inc

    STUDY DIRECTOR

Central Study Contacts

Patients Contact: Trial Recruitment

CONTACT

HCPs Contact: Medical Information

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2016

First Posted

March 23, 2016

Study Start

April 25, 2016

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations